European Journal of Surgical Oncology
Volume 36, Issue 2 , Pages 164-169 , February 2010

Identification of residual breast tumour localization after neo-adjuvant chemotherapy using a radioactive 125 Iodine seed

  • Y.E.A. van Riet

      Affiliations

    • Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
    • Corresponding Author InformationCorresponding author at: Catharina Hospital, Department of Surgery, PO Box 1350, 5602 ZA Eindhoven, The Netherlands. Tel.: 31402397155; fax: +31 40 2443370.
    • ,
  • A.J.G. Maaskant

      Affiliations

    • Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
    • ,
  • G.J. Creemers

      Affiliations

    • Department of Medical Oncology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
    • ,
  • L.J.C. van Warmerdam

      Affiliations

    • Department of Medical Oncology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
    • ,
  • F.H. Jansen

      Affiliations

    • Department of Radiology, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
    • ,
  • C.J.H. van de Velde

      Affiliations

    • Department of Surgery, University Hospital, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    • ,
  • H.J.T. Rutten

      Affiliations

    • Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands
    • ,
  • G.A.P. Nieuwenhuijzen

      Affiliations

    • Department of Surgery, Catharina Hospital, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands

,Accepted 13 October 2009.

References 

  1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 2001;19:4224–4237
  2. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672–2685
  3. Buchholz TA, Hunt KK, Whitman GJ, Sahin AA, Hortobagyi GN. Neo-adjuvant chemotherapy for breast carcinoma, multidisciplinary considerations of benefits and risks. Cancer. 2003;98:1150–1160
  4. Estevez LG, Gradishar WJ. Evidence based use of neo-adjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004;10:3249–3261
  5. NSABP Group . The effect on primary tumor response of adding sequential Taxotere to Adriamycin and cyclophosphamide: preliminary results from NSABP Protocol B-27. Breast Cancer Res Treat. 2001;69:210–214
  6. Rouzier R, Mathieu M, Sideris L, et al. Breast-conserving surgery after neo-adjuvant anthracycline-based chemotherapy for large breast tumors. Cancer. 2004;101:918–925
  7. Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimetres or more. J Natl Cancer Inst. 1990;82:1539–1545
  8. Chen A, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neo-adjuvant chemotherapy: the M.D. Anderson cancer experience. J Clin Oncol. 2004;22:2303–2312
  9. Chen A, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neo-adjuvant chemotherapy. A prognostic index for clinical decision-making. Cancer. 2005;103:689–695
  10. Mauriac L, Macgrogan G, Avril A, et al. Neo-adjuvant chemotherapy for operable breast carcinoma larger than 3cm: a unicentre randomized trial with a 124-month median follow-up. Ann Oncol. 1999;47–52
  11. Kulkarni S, Hicks DG. HER2-positive early breast cancer and trastuzumab: a surgeon's perspective. Ann Surg Oncol. 2008;15:1677–1688
  12. Mathew J, Asgeirsson KS, Cheung KL, Chan , et al. Neo-adjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol. 2009;35:113–122
  13. Shenoy HG, Peter MB, Massanat YA, et al. Practical advice on clinical decision making during neoadjuvant chemotherapy for primary breast cancer. Surg Oncol. 2008 Aug;[Epub ahead of print]
  14. Gray RJ, Salud C, Nguyen K, et al. Randomized prospective evaluation of a novel technique for biopsy or lumpectomy of non-palpable breast lesions: radioactive seed versus wire localization. Ann Surg Oncol. 2001;8:711–715
  15. Gray RJ, Giuliano R, Dauway EL, Cox CE, Reintgen DS. Radioguidance for nonpalpable primary lesions and sentinel lymph node(s). Am J Surg. 2001;182:404–406
  16. Hughes JH, Mason MC, Gray RJ, et al. A multi- site validation trial of radioactive seed localization as an alternative to wire localization. Breast J. 2008;14:153–157
  17. Pavlicek W, Walton HA, Karstaedt PJ, et al. Radiation safety with use of I-125 seeds for localization of non-palpable breast lesions. Acad Radiol. 2006;13:909–915
  18. Valenzuela M. Julian TB Neo-adjuvant hormonal therapy. Breast J. 2008;14(3):279–283
  19. Mieog JS, van Nes JG, van de Velde CJ. The advantages of preoperative systemic therapy in breast cancer, Ned Tijdschr Geneeskd. 2008;152(46):2501–2506
  20. New response evaluation. Criteria in Solid Tumours: Revised RECIST criteria (version 1.1) E.A. Eisenhauer, P. Therasse, J. Bogaerts et al. 20th EORTC-NCI-AACR Symposium Molecular Targets and Cancer Therapeutics Geneva, Switzerland (21–24 October 2008) (published Eur J Cancer 2009)
  21. Bosch AM, Kessels AGH, Beets GL, et al. Pre-operative estimation of the pathological breast tumour size by physical examination, mammography and ultrasound: a prospective study on 105 invasive tumours. Eur J Radiol. 2003;48:285–292
  22. Seymour MT, Moskovic EC, Walsh G, et al. Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer. Br J Cancer. 1997;76:371–376
  23. Loo CE, Teertstra HJ, Rodenhuis S, et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. Am J Roentgenol. 2008;191:1331–1338
  24. Londero V, Bazzocchi M, Del Frate C, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neo-adjuvant chemotherapy. Eur Radiol. 2004;14:1371–1379
  25. Belli P, Constantini M, Malpaspina C, et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. Clin Radiol. 2006;61:946–953
  26. Edeiken BS, Fornage BD, Bedi DG, et al. US-guided implantation of metallic markers for permanent localization of the tumor bed in patients with breast cancer who undergo preoperative chemotherapy. Radiology. 1999;213:895–900
  27. Cleator S, Heller W, Coombes RC. Tripple – negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235–244
  28. Liedtke C, Manzouni C, Hess KR, et al. Response to neo-adjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26:1275–1281
  29. Velanovich V, Lewis FR, Nathanson SD, et al. Comparison of mammographically guided breast biopsy techniques. Ann Surg. 1999;229:625–633
  30. Gray RJ, Pockay BA, Karstaedt PJ, Roarke MC. Radioactive seed localization of nonpalpable breast lesions is better than wire localization. Am J Surg. 2004 Oct;188:377–380

PII: S0748-7983(09)00481-8

doi: 10.1016/j.ejso.2009.10.009

European Journal of Surgical Oncology
Volume 36, Issue 2 , Pages 164-169 , February 2010

Article Tools